$CELC
Celcuity Inc.

2018 Q3 Form 10-Q Financial Statement

#000114420418043344 Filed on August 09, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $380.0K $380.0K $300.0K
YoY Change 137.5% 26.67% 328.57%
% of Gross Profit
Research & Development $1.599M $1.547M $1.304M
YoY Change 17.17% 18.61% 73.85%
% of Gross Profit
Depreciation & Amortization $62.81K $49.97K $25.72K
YoY Change 104.5% 94.25% 28.61%
% of Gross Profit
Operating Expenses $1.976M $1.929M $1.606M
YoY Change 29.19% 20.15% 95.82%
Operating Profit -$1.976M -$1.929M -$1.606M
YoY Change 29.19% 20.15%
Interest Expense $65.00 $0.00 $186.7K
YoY Change -99.98% -100.0%
% of Operating Profit
Other Income/Expense, Net $104.7K $112.7K -$170.5K
YoY Change -144.65% -166.11%
Pretax Income -$1.871M -$1.816M -$1.776M
YoY Change 6.07% 2.27% 116.61%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.871M -$1.816M -$1.776M
YoY Change 6.07% 2.27% 116.61%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$184.6K -$180.0K -$190.0K
COMMON SHARES
Basic Shares Outstanding 10.12M shares 10.11M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.76M $21.56M $10.91M
YoY Change -30.08% 97.62%
Cash & Equivalents $3.809M $3.173M $10.91M
Short-Term Investments $18.95M $18.39M
Other Short-Term Assets $400.0K $230.0K $520.0K
YoY Change 21.21% -55.77%
Inventory
Prepaid Expenses $352.3K $154.0K
Receivables
Other Receivables
Total Short-Term Assets $23.16M $21.79M $11.42M
YoY Change -29.54% 90.81%
LONG-TERM ASSETS
Property, Plant & Equipment $814.1K $730.4K $270.0K
YoY Change 201.5% 170.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.920M $6.950M
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.734M $7.679M $270.0K
YoY Change 1590.73% 2744.09%
TOTAL ASSETS
Total Short-Term Assets $23.16M $21.79M $11.42M
Total Long-Term Assets $4.734M $7.679M $270.0K
Total Assets $27.89M $29.47M $11.69M
YoY Change -15.85% 152.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $177.7K $149.4K $520.0K
YoY Change 492.29% -71.27%
Accrued Expenses $777.2K $807.8K $260.0K
YoY Change 159.07% 210.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K
YoY Change
Total Short-Term Liabilities $960.6K $962.9K $780.0K
YoY Change 182.53% 23.45%
LONG-TERM LIABILITIES
Long-Term Debt $20.00K $20.00K $0.00
YoY Change
Other Long-Term Liabilities $6.580M
YoY Change
Total Long-Term Liabilities $20.00K $20.00K $6.580M
YoY Change -99.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $960.6K $962.9K $780.0K
Total Long-Term Liabilities $20.00K $20.00K $6.580M
Total Liabilities $981.9K $986.1K $7.350M
YoY Change 188.8% -86.58%
SHAREHOLDERS EQUITY
Retained Earnings -$7.663M -$5.792M
YoY Change
Common Stock $10.15K $10.12K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.91M $28.48M $4.330M
YoY Change
Total Liabilities & Shareholders Equity $27.89M $29.47M $11.69M
YoY Change -15.85% 152.09%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$1.871M -$1.816M -$1.776M
YoY Change 6.07% 2.27% 116.61%
Depreciation, Depletion And Amortization $62.81K $49.97K $25.72K
YoY Change 104.5% 94.25% 28.61%
Cash From Operating Activities -$1.780M -$1.330M -$1.260M
YoY Change 9.2% 5.56% 65.79%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K -$170.0K -$160.0K
YoY Change 266.67% 6.25% 1500.0%
Acquisitions
YoY Change
Other Investing Activities $2.480M $2.030M
YoY Change -1092.0%
Cash From Investing Activities $2.380M $1.850M -$160.0K
YoY Change -950.0% -1256.25% 1500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -10.00K 80.00K 7.430M
YoY Change -100.04% -98.92% 301.62%
NET CHANGE
Cash From Operating Activities -1.780M -1.330M -1.260M
Cash From Investing Activities 2.380M 1.850M -160.0K
Cash From Financing Activities -10.00K 80.00K 7.430M
Net Change In Cash 590.0K 600.0K 6.010M
YoY Change -97.24% -90.02% 456.48%
FREE CASH FLOW
Cash From Operating Activities -$1.780M -$1.330M -$1.260M
Capital Expenditures -$110.0K -$170.0K -$160.0K
Free Cash Flow -$1.670M -$1.160M -$1.100M
YoY Change 4.37% 5.45% 46.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-weight:bold;display:inline;">Accounting Estimates</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and warrants issued to investors, a placement agent and an underwriter, and prepaid or accrued clinical trial costs.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Depreciation
Depreciation
89704 USD
us-gaap Depreciation
Depreciation
45449 USD
CY2018Q2 us-gaap Depreciation
Depreciation
49966 USD
CY2017Q2 us-gaap Depreciation
Depreciation
25722 USD
CY2018Q2 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
544804 USD
CY2017Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
389802 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
501603 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
302088 shares
CY2018Q2 celc Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedremainder Of Fiscal Year
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedremainderOfFiscalYear
394516 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3172782 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10908068 USD
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
77419 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
522755 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M20D
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
188850 USD
CY2018Q2 us-gaap Restricted Cash
RestrictedCash
50000 USD
CY2017Q2 us-gaap Restricted Cash
RestrictedCash
50000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3784407 USD
us-gaap Net Income Loss
NetIncomeLoss
-2763566 USD
CY2018Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
74652 USD
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
0 USD
CY2018Q2 celc Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Two Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinTwoYears
515020 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
21152 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
148150 shares
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1546537 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1303886 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3092205 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2212629 USD
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q2 us-gaap Prepaid Insurance
PrepaidInsurance
47917 USD
CY2017Q4 us-gaap Prepaid Insurance
PrepaidInsurance
162914 USD
CY2018Q2 us-gaap Prepaid Rent
PrepaidRent
21490 USD
CY2017Q4 us-gaap Prepaid Rent
PrepaidRent
21673 USD
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2639789 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
913286 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
386963 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
382646 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
301820 USD
CY2018Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
66324 USD
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
61829 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7553 shares
CY2018Q2 celc Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Three Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinThreeYears
336530 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3222782 USD
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10958068 USD
dei Document Type
DocumentType
10-Q
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
193338 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.04
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8771626 USD
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
64940 USD
dei Amendment Flag
AmendmentFlag
false
CY2018Q2 celc Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Four Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinFourYears
153773 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
442685 shares
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
122003 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
54509 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"><div style="font-weight:bold;display:inline;">Risks and Uncertainties</div></div></div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: &quot;times new roman&quot;, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
1929183 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
1605706 USD
us-gaap Operating Expenses
OperatingExpenses
4005491 USD
us-gaap Operating Expenses
OperatingExpenses
2599592 USD
CY2018Q2 us-gaap Short Term Investments
ShortTermInvestments
18385920 USD
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
21556857 USD
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
84595 USD
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
25121 USD
CY2018Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
154002 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
209708 USD
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1078013 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
540175 USD
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000 USD
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4005491 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2599592 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1929183 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1605706 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
262393 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
166119 shares
CY2018Q2 celc Employee Service Sharebased Compensation Nonvested Awards Compensation Cost Not Yet Recognizedwithin Five Years
EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognizedwithinFiveYears
10905 USD
us-gaap Share Based Compensation
ShareBasedCompensation
612764 USD
us-gaap Share Based Compensation
ShareBasedCompensation
422816 USD
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
us-gaap Other Noncash Expense
OtherNoncashExpense
186759 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.02 pure
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.76 pure
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
524547 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75 pure
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.72
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1410744 USD
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
276284 USD
CY2017Q2 us-gaap Share Based Compensation
ShareBasedCompensation
326548 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.58
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.91
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
43198 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
25077 USD
CY2018Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
30009 USD
CY2017Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
12668 USD
CY2018Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
27726 USD
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
27726 USD
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000 shares
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
347564 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
260119 USD
CY2018Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
353980 shares
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
103864 shares
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
730449 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
280056 USD
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10119312 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10087516 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.93
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.38
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4748003 USD
CY2018Q2 us-gaap Interest Expense
InterestExpense
0 USD
CY2017Q2 us-gaap Interest Expense
InterestExpense
186659 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
186686 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
dei Entity Registrant Name
EntityRegistrantName
Celcuity Inc.
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-55706 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
156120 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.60
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
112722 USD
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
16150 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
221084 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
22712 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
21790430 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
24484080 USD
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10087516 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10119312 shares
CY2017Q2 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
300000 USD
CY2017Q4 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
50000 USD
CY2018Q2 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
50000 USD
CY2018Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
50000 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.78
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12604 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-34771 USD
dei Entity Central Index Key
EntityCentralIndexKey
0001603454
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
112722 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-170509 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
221084 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-163974 USD
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
226643 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
89700 USD
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.46
CY2018Q2 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
100000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3784407 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2763566 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1816461 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1776215 USD
CY2018Q2 us-gaap Long Term Investments
LongTermInvestments
6948606 USD
CY2017Q4 us-gaap Long Term Investments
LongTermInvestments
7205374 USD
CY2018Q2 us-gaap Assets
Assets
29469485 USD
CY2017Q4 us-gaap Assets
Assets
31969510 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q2 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
50000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.29
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2784281 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2209733 USD
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
CELC
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
2571 shares
CY2018Q2 us-gaap Contractual Obligation
ContractualObligation
2040000 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
2571 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
0 shares
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10119312 shares
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
3235000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 USD
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
6660000 USD
us-gaap Proceeds From Sale Of Other Investments
ProceedsFromSaleOfOtherInvestments
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
5250 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
5250 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0 shares
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
149401 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
71913 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
372282 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
165851 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2018Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
5706 USD
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
0 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
962890 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
578053 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3053718 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-165851 USD
CY2018Q2 us-gaap Liabilities
Liabilities
986116 USD
CY2017Q4 us-gaap Liabilities
Liabilities
578053 USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q2 celc Class Of Warrant Or Rightterm
ClassOfWarrantOrRightterm
P10Y
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7493330 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
40961 USD
CY2017Q2 celc Debt Insrtument Commission Percentage
DebtInsrtumentCommissionPercentage
0.1 pure
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33388597 USD
CY2018Q2 us-gaap Held To Maturity Securities Amortized Cost Before Other Than Temporary Impairment
HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment
25334526 USD
CY2017Q4 us-gaap Held To Maturity Securities Amortized Cost Before Other Than Temporary Impairment
HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment
28762231 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
532993 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5051720 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5791634 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2007227 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2689789 USD
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5906348 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
28483369 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
31391457 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
29469485 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31969510 USD
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
10119 USD
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
10087 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
34264884 USD
CY2017Q2 celc Proceeds From Issuance Of Convertible Debt Gross
ProceedsFromIssuanceOfConvertibleDebtGross
8337500 USD
CY2018Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
353980 shares
CY2017Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
373323 shares
celc Investment Warrant Exercise Price
InvestmentWarrantExercisePrice
9.42
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-1816461 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1776215 USD
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10103323 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6440139 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10110558 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6440139 shares
celc Non Cash Interest Income Adjustment
NonCashInterestIncomeAdjustment
2705 USD
celc Non Cash Interest Income Adjustment
NonCashInterestIncomeAdjustment
0 USD
celc Payments For Deferred Trasaction Costs
PaymentsForDeferredTrasactionCosts
0 USD
celc Payments For Deferred Trasaction Costs
PaymentsForDeferredTrasactionCosts
25065 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
183759 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
807783 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
506140 USD
CY2018Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
23226 USD
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0 USD
CY2018Q2 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
28932 USD
CY2018Q2 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
482 USD
CY2018Q2 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
28450 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
79797 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0 USD
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
4232 USD
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
7255 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
263556 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7427304 USD
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
7255 USD
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
7255 USD
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due In Five Years
CapitalLeasesFutureMinimumPaymentsDueInFiveYears
7255 USD
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due Thereafter
CapitalLeasesFutureMinimumPaymentsDueThereafter
3022 USD
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
36274 USD
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
512 USD
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Executory Costs
CapitalLeasesFutureMinimumPaymentsExecutoryCosts
6830 USD
CY2018Q2 us-gaap Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments
CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
28932 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
64883 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
28932 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
celc Leasehold Improvements Funded By Landlord And Related Deferred Rent Included In Accrued Expenses
LeaseholdImprovementsFundedByLandlordAndRelatedDeferredRentIncludedInAccruedExpenses
75000 USD
celc Leasehold Improvements Funded By Landlord And Related Deferred Rent Included In Accrued Expenses
LeaseholdImprovementsFundedByLandlordAndRelatedDeferredRentIncludedInAccruedExpenses
0 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
844170 USD
CY2018Q2 celc Lessee Capital Lease Term Of Contract
LesseeCapitalLeaseTermOfContract
P5Y
celc Debt Discount Related To Investor And Agent Warrant
DebtDiscountRelatedToInvestorAndAgentWarrant
0 USD
celc Debt Discount Related To Investor And Agent Warrant
DebtDiscountRelatedToInvestorAndAgentWarrant
1063715 USD
celc Deferred Transaction Costs Included In Accounts Payable And Accrued Expenses
DeferredTransactionCostsIncludedInAccountsPayableAndAccruedExpenses
0 USD
celc Deferred Transaction Costs Included In Accounts Payable And Accrued Expenses
DeferredTransactionCostsIncludedInAccountsPayableAndAccruedExpenses
276666 USD

Files In Submission

Name View Source Status
0001144204-18-043344-index-headers.html Edgar Link pending
0001144204-18-043344-index.html Edgar Link pending
0001144204-18-043344.txt Edgar Link pending
0001144204-18-043344-xbrl.zip Edgar Link pending
celc-20180630.xml Edgar Link completed
celc-20180630.xsd Edgar Link pending
celc-20180630_cal.xml Edgar Link unprocessable
celc-20180630_def.xml Edgar Link unprocessable
celc-20180630_lab.xml Edgar Link unprocessable
celc-20180630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tv499834_10q.htm Edgar Link pending
tv499834_ex3-1.htm Edgar Link pending
tv499834_ex31-1.htm Edgar Link pending
tv499834_ex31-2.htm Edgar Link pending
tv499834_ex32-1.htm Edgar Link pending
tv499834_ex32-2.htm Edgar Link pending